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2770REPLY: Underutilization of High-Intensity
Statin Therapy After Hospitalization for
Coronary Heart Disease
A Cause for Concern, But a Few Words of CautionThe 2013 American Heart Association/American Col-
lege of Cardiology (ACC/AHA) Guidelines on the
treatment of blood cholesterol to reduce atheroscle-
rotic cardiovascular risk in adults (1) represent
a paradigm shift in the approach to utilization of
statin therapy for individuals with established
atherosclerotic cardiovascular disease (CVD) who are
at substantially higher risk for recurrent events
particularly after an acute coronary syndrome (ACS).
In response to our recent publication, Drs. Nguyen
and Biron question the validity of the evidence used
to generate the ACC/AHA guideline. They cite 2 post-
ACS trials that reported small reductions in the
cardiovascular and mortality endpoints (2,3). Addi-
tionally, they note recent reports as well as anecdotes
from their own institution of possible adverse events
associated with high-intensity statin use. We would
like to clarify some of the points they raise and provide
justiﬁcation as to why we believe high-intensity sta-
tins are currently underutilized following ACS events.
Given the limited duration of follow-up, the absolute
beneﬁt of high-intensity statins in randomized trials
has been small. However, extrapolating data from
the PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis In
Myocardial Infarction 22) trial to 10 years would
demonstrate a substantially larger (6.8) absolute risk
reduction in the pooled outcome of death/nonfatal MI.
Additionally, Drs. Nguyen and Biron cite observational
data and anecdotes on the safety of high-intensity
statin therapy. These data need to be placed into an
appropriate context. For example, the CVD risk
reduction beneﬁts of statins have been shown to
outweigh the risk for new-onset diabetes. Also, the
increased risk for acute kidney injury with high-
intensity statins is unclear and we believe requires
further study.
In our analysis of Medicare participants hospital-
ized for a CHD event, 27% were treated with high-
intensity statin. In order to minimize inappropriate
use of high-intensity statin therapy, we excluded
participants’ $75 years of age and those with end-
stage renal disease (4). Additionally, we reported
the use of high-intensity statins in multiple sub-
groups. In every subgroup, including participants
without comorbidities, the use of high-intensity
statins was <30%. We acknowledge that Medicareclaims data did not have information on prior statin
intolerance or adverse events and appropriate rea-
sons for providers to not prescribe high-intensity
statins. Nonetheless, it is our opinion that the evi-
dence used to justify ACC/AHA guidelines are strong
that most patients should be discharged on high-
intensity statins after an ACS event. Clearly there
will be patients for whom high-potency statins are
not appropriate. However, it is unreasonable that we
should accept only 1 in 4 patients being discharged on
high-intensity statins after an ACS event represents
optimal medical management.
Future studies are needed to identify the barriers
to broader use of high-potency statins among pa-
tients with established CHD events. Additionally,
physician misperception on the risks and beneﬁts
associated with high-intensity statins evidently also
need to be addressed. Given the risk reduction
beneﬁts demonstrated in randomized controlled tri-
als, increasing the appropriate use of high-intensity
statins for the proper patients should be a high
priority for cardiologists and other healthcare
providers.*Robert S. Rosenson, MD
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